NEW YORK, Feb. 7, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on ELGX, GKOS, and MZOR, which can be accessed for free by signing up to www.wallstequities.com/registration. This morning, WallStEquities.com scans Endologix Inc. (NASDAQ: ELGX), Glaukos Corp. (NYSE: GKOS),
On Tuesday, shares in Irvine, California headquartered Endologix Inc. recorded a trading volume of 925,730 shares, which was above their three months average volume of 602,960 shares. The stock ended at $4.08, declining 1.45% from the last trading session. The Company's shares are trading below their 50-day moving average by 16.90%. Furthermore, shares of Endologix, which develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the US and internationally, have a Relative Strength Index (RSI) of 28.78.
On January 25th, 2018, Endologix announced that it will report financial results for Q4 FY17 and FY17 after the market close on February 21st, 2018. Management will host a conference call at 4:30 p.m. ET that same day to discuss the results. This call will be webcast and can be accessed under the "Investors" section of the Company's website. Get the full research report on ELGX for free by clicking below at: www.wallstequities.com/registration/?symbol=ELGX
San Clemente, California headquartered Glaukos Corp.'s stock finished yesterday's session 1.93% higher at $29.52 with a total trading volume of 445,571 shares. The Company's shares have gained 12.46% in the last month. The stock is trading above its 50-day moving average by 7.75%. Furthermore, shares of Glaukos, which focuses on the development and commercialization of products and procedures designed to treat glaucoma, have an RSI of 55.45.
On January 10th, 2018, Glaukos announced that its Travoprost Intraocular Implant with the iDose™ delivery system continued to provide sustained reduction in intraocular pressure in a 12-month interim cohort of patients in its US Investigational New Drug (IND) Phase-II clinical trial. The Company also announced that it conducted a productive End-of-Phase-II Meeting with the FDA in late 2017 and is currently making preparations to initiate a Phase III IND clinical trial in the first half of 2018. The free technical report on GKOS can be accessed at: www.wallstequities.com/registration/?symbol=GKOS
At the close of trading on Tuesday, shares in Caesarea, Israel-based Mazor Robotics Ltd saw a slight decline of 0.83%, ending the day at $61.78. The stock recorded a trading volume of 648,627 shares, which was above its three months average volume of 538,920 shares. The Company's shares have advanced 8.42% in the last month, 2.57% in the previous three months, and 164.92% over the past year. The stock is trading 6.50% and 30.31% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Mazor Robotics, which together with its subsidiary, Mazor Robotics Inc., is engaged in the development, production, marketing, and servicing of medical devices for supporting surgical procedures in the fields of orthopedics and neurosurgery in the US, Western Europe, Eastern Europe, and Asia, have an RSI of 53.54.
On January 30th, 2018, Mazor Robotics announced that it will report financial results for Q4 and full year ended December 31st, 2017 before the US markets open on February 14th, 2018. The Company will host a conference call at 8:30 a.m. EST that same day to discuss these results. The webcast can be accessed under the "Investor Relations" section of the Company's website. Sign up for free on Wall St. Equities and claim the latest report on MZOR at: www.wallstequities.com/registration/?symbol=MZOR
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-medical-supplies-stocks----endologix-glaukos-and-mazor-robotics-300594882.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!